Hydrochlorothiazide; irbesartan - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for hydrochlorothiazide; irbesartan and what is the scope of freedom to operate?
Hydrochlorothiazide; irbesartan
is the generic ingredient in two branded drugs marketed by Sanofi Aventis Us, Alembic, Apotex Inc, Atlas Pharms Llc, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Hikma, Hisun Pharm Hangzhou, Lupin Ltd, Macleods Pharms Ltd, Norvium Bioscience, Prinston Inc, Sandoz, Teva, Unichem, and Watson Labs Inc, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.Thirteen suppliers are listed for this compound. There are six tentative approvals for this compound.
Summary for hydrochlorothiazide; irbesartan
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 16 |
NDAs: | 16 |
Finished Product Suppliers / Packagers: | 13 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 15 |
Patent Applications: | 166 |
DailyMed Link: | hydrochlorothiazide; irbesartan at DailyMed |
Recent Clinical Trials for hydrochlorothiazide; irbesartan
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Damanhour University | N/A |
Roxane Laboratories | N/A |
Sanofi | Phase 4 |
Generic filers with tentative approvals for HYDROCHLOROTHIAZIDE; IRBESARTAN
Applicant | Application No. | Strength | Dosage Form |
⤷ Subscribe | ⤷ Subscribe | 12.5MG;300MG | TABLET;ORAL |
⤷ Subscribe | ⤷ Subscribe | 12.5MG;150MG | TABLET;ORAL |
⤷ Subscribe | ⤷ Subscribe | 25MG;300MG | TABLET; ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for hydrochlorothiazide; irbesartan
Drug Class | Angiotensin 2 Receptor Blocker Thiazide Diuretic |
Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for hydrochlorothiazide; irbesartan
Paragraph IV (Patent) Challenges for HYDROCHLOROTHIAZIDE; IRBESARTAN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
AVALIDE | Tablets | hydrochlorothiazide; irbesartan | 300 mg/25 mg | 020758 | 1 | 2006-06-06 |
AVALIDE | Tablets | hydrochlorothiazide; irbesartan | 150 mg/12.5 mg and 300 mg/12.5 mg | 020758 | 1 | 2004-11-10 |
US Patents and Regulatory Information for hydrochlorothiazide; irbesartan
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva | IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 077369-001 | Mar 30, 2012 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Atlas Pharms Llc | IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 203036-003 | Jan 15, 2016 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Prinston Inc | IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 203072-002 | May 9, 2014 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Norvium Bioscience | IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 077969-003 | Jul 20, 2016 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Atlas Pharms Llc | IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 203036-002 | Jan 15, 2016 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Apotex Inc | IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 201505-002 | Oct 15, 2012 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Alembic | IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 091370-001 | Oct 15, 2012 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for hydrochlorothiazide; irbesartan
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | AVALIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 020758-004 | Mar 15, 2005 | 5,270,317*PED | ⤷ Subscribe |
Sanofi Aventis Us | AVALIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 020758-001 | Sep 30, 1997 | 5,270,317*PED | ⤷ Subscribe |
Sanofi Aventis Us | AVALIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 020758-003 | Aug 31, 1998 | 5,994,348*PED | ⤷ Subscribe |
Sanofi Aventis Us | AVALIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 020758-004 | Mar 15, 2005 | 5,994,348*PED | ⤷ Subscribe |
Sanofi Aventis Us | AVALIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 020758-003 | Aug 31, 1998 | 5,270,317*PED | ⤷ Subscribe |
Sanofi Aventis Us | AVALIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 020758-002 | Sep 30, 1997 | 5,994,348*PED | ⤷ Subscribe |
Sanofi Aventis Us | AVALIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 020758-001 | Sep 30, 1997 | 5,994,348*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for hydrochlorothiazide; irbesartan
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
sanofi-aventis groupe | Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop) | irbesartan, hydrochlorothiazide | EMEA/H/C/000783 Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone. |
Authorised | no | no | no | 2007-01-18 | |
Sanofi Winthrop Industrie | Karvezide | irbesartan, hydrochlorothiazide | EMEA/H/C/000221 Treatment of essential hypertension.This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone. |
Authorised | no | no | no | 1998-10-16 | |
Sanofi Winthrop Industrie | CoAprovel | irbesartan, hydrochlorothiazide | EMEA/H/C/000222 Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone. |
Authorised | no | no | no | 1998-10-14 | |
Krka, d.d., Novo mesto | Ifirmacombi | irbesartan, hydrochlorothiazide | EMEA/H/C/002302 Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone. |
Authorised | yes | no | no | 2011-03-04 | |
Teva B.V. | Irbesartan/Hydrochlorothiazide Teva | irbesartan, hydrochlorothiazide | EMEA/H/C/001112 Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone. |
Authorised | yes | no | no | 2009-11-26 | |
Bristol-Myers Squibb Pharma EEIG | Irbesartan Hydrochlorothiazide BMS | irbesartan, hydrochlorothiazide | EMEA/H/C/000784 Treatment of essential hypertension.This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1). |
Withdrawn | no | no | no | 2007-01-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
Hydrochlorothiazide; irbesartan Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.